Protavio presented its latest work on melanoma research at the 11th European Workshops on Cell Death and 3rd MelPlex Annual Meeting held in Fiuggi, Italy, between 4-11th May.
Protavio's Jan Rozanc presented his latest findings on how "phosphoprotein patterns allow prediction of trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma." The work is part of the MelPlex program, a Horizon 2020 Marie Curie Action, that aims to improve our understanding on the mechanisms underpinning melanoma in a systems oriented framework and generate a solid basis for the development and validation of diagnostic and predictive tools for personalised cancer therapies.
In his talk at the MelPlex supervisory board meeting, Protavio's Leo Alexopoulos emphasised the importance of commercialisation and IP exploitation of the translational research outcomes of MelPlex. Prof Alexopoulos discussed the three areas where intellectual property rights can be explored and protected: a) the compounds, in the form of new compositions, new formulations or new indications (repositioning), b) the methods, specifically the in-silico, in-vitro and in-vivo models of drug discovery in melanoma and c) the biomarkers, in the form of an In-vitro Diagnostic (IVD) or Laboratory Developed Test (LDT) of prognostic, predictive or diagnostic value.
For more information on Protavio's work on melanoma, please contact us here or write to us at firstname.lastname@example.org
For more information on the MelPlex programme visit melplex.eu.
Protavio is a drug and biomarker discovery solutions provider for the Pharmaceutical, Diagnostics and Life Sciences sectors. Using advanced in-vitro and in-silico approaches and proprietary technology, we deliver fast and experimentally proven services for compound evaluation (target identification, efficacy, toxicity, mode-of-action, drug repositioning) and biomarker discovery and performance analysis. To learn more, visit www.protavio.com